Studies have shown that active fund managers routinely underperform the S&P500 index*​

Bicycle Therapeutics plc (NASDAQ: BCYC)

BCYC Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-47.60%
Analyst Rating:
BUY
Analyst Forecast (1yr):
188.70%

BCYC Stock Analysis

BCYC PE Ratio:

BCYC PEG Ratio: Not Available

BCYC Forward EPS Growth (12 month): 0.00%

BCYC PS Ratio: 4.6

BCYC PSG Ratio: -0.1

BCYC Forward Revenue Growth (12 month): -44.40%

BCYC Articles

No data was found